Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:antiviral_drug
|
| gptkbp:alternativeName |
Ensitrelvir
|
| gptkbp:ATCCode |
J05AX
|
| gptkbp:CASNumber |
2647539-45-3
|
| gptkbp:chemicalClass |
gptkb:small_molecule
|
| gptkbp:clinicalTrialPhase |
Phase 2/3
|
| gptkbp:developedBy |
gptkb:Shionogi_&_Co.
|
| gptkbp:intendedUse |
treatment of COVID-19
|
| gptkbp:marketedAs |
Xocova (in Japan)
|
| gptkbp:mechanismOfAction |
main protease inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
approved in Japan for emergency use |
| gptkbp:target |
SARS-CoV-2 main protease (Mpro)
|
| gptkbp:bfsParent |
gptkb:Wisconsin_Highway_87
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
STH-87
|